TIMOTHY MCAFEE: Open Payments
NPI 1548851785 · MILAN, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$203 in 11 payments from 6 companies in 2025. Trend: 2023 $109 · 2024 $0 · 2025 $203
Food & beverage: $203
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $62 |
| Otsuka America Pharmaceutical, Inc. | 3 | $54 |
| ABBVIE INC. | 2 | $37 |
| GlaxoSmithKline, LLC. | 1 | $22 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $15 |
| PFIZER INC. | 1 | $14 |
Products named: CAPLYTA, REXULTI, TRELEGY ELLIPTA, QULIPTA, VRAYLAR, XIFAXAN, PREVNAR 20.
Industry payments across IN — which companies pay providers there.
